Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.4600 (-2.33%) ($5.2600 - $5.5900) on Fri. Oct. 18, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.51% (three month average) | RSI | 43 | Latest Price | $5.4600(-2.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.9% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.9% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.755% in a week (0% probabilities). VIXM(-39%) VXX(-37%) TLT(-8%) UUP(-7%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.755% (StdDev 3.51%) | Hourly BBV | 0 () | Intraday Trend | -1.1% | | | |
|
5 Day Moving Average | $5.39(1.3%) | 10 Day Moving Average | $5.29(3.21%) | 20 Day Moving Average | $5.39(1.3%) | To recent high | -31.5% | To recent low | 7.1% | Market Cap | $692m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |